Fractyl Health (GUTS) to Release Quarterly Earnings on Monday

Fractyl Health (NASDAQ:GUTS) is expected to release its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of ($0.19) per share for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 4:30 PM ET.

Fractyl Health Trading Down 1.1%

NASDAQ:GUTS opened at $0.47 on Friday. The stock has a 50 day simple moving average of $1.37 and a 200 day simple moving average of $1.35. Fractyl Health has a 1-year low of $0.38 and a 1-year high of $3.03. The stock has a market cap of $64.31 million, a P/E ratio of -0.20 and a beta of 1.64.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on GUTS. Weiss Ratings reissued a “sell (d-)” rating on shares of Fractyl Health in a research report on Monday, December 29th. Morgan Stanley downgraded shares of Fractyl Health from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $8.00 to $2.00 in a report on Thursday, January 29th. Canaccord Genuity Group restated a “buy” rating and set a $8.00 target price on shares of Fractyl Health in a research report on Friday, December 19th. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Fractyl Health in a research report on Tuesday, December 2nd. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Fractyl Health has a consensus rating of “Hold” and an average target price of $5.40.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in GUTS. Bank of America Corp DE boosted its holdings in shares of Fractyl Health by 23.5% in the 3rd quarter. Bank of America Corp DE now owns 88,634 shares of the company’s stock valued at $141,000 after purchasing an additional 16,856 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Fractyl Health during the 2nd quarter worth $31,000. Jump Financial LLC acquired a new stake in Fractyl Health in the fourth quarter valued at about $57,000. Scientech Research LLC bought a new position in Fractyl Health in the third quarter valued at about $49,000. Finally, Prelude Capital Management LLC bought a new position in Fractyl Health in the third quarter valued at about $55,000.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.